Limits...
Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Harm S, Gabor F, Hartmann J - Innate Immun (2016)

Bottom Line: The formed LPS-PMB complex has lower inflammatory activity in blood, which results in highly reduced cytokine secretion.Furthermore, the combination of cytokine removal by adsorbent treatment with LPS inactivation by PMB dosage leads to strong suppression of inflammatory effects in blood in an in vitro model.Inactivation of endotoxins by low-dose intravenous PMB infusion or infusion into the extracorporeal circuit during blood purification can be applied to overcome the urgent need for endotoxin elimination not only in treatment of sepsis, but also in liver failure.

View Article: PubMed Central - PubMed

Affiliation: Department for Health Sciences and Biomedicine, Danube University Krems, Krems, Austria Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstra├če 14, A-1090 Vienna, Austria stephan.harm@donau-uni.ac.at.

No MeSH data available.


Related in: MedlinePlus

Scheme of the experiment where three different treatment options: (i) adsorbent combined with PMB; (ii) adsorbent treatment only; (iii) PMB treatment only. The influence on inflammation was tested by determination of the cytokine levels after incubation of differently pre-treated plasma samples with native blood cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4834512&req=5

fig1-1753425916639120: Scheme of the experiment where three different treatment options: (i) adsorbent combined with PMB; (ii) adsorbent treatment only; (iii) PMB treatment only. The influence on inflammation was tested by determination of the cytokine levels after incubation of differently pre-treated plasma samples with native blood cells.

Mentions: To verify whether the combination of adsorptive cytokine removal and PMB infusion is more effective than one of these treatments, an experiment as schematically displayed in Figure 1 was conducted. This experiment was carried out with blood from three different volunteers.Figure 1.


Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Harm S, Gabor F, Hartmann J - Innate Immun (2016)

Scheme of the experiment where three different treatment options: (i) adsorbent combined with PMB; (ii) adsorbent treatment only; (iii) PMB treatment only. The influence on inflammation was tested by determination of the cytokine levels after incubation of differently pre-treated plasma samples with native blood cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4834512&req=5

fig1-1753425916639120: Scheme of the experiment where three different treatment options: (i) adsorbent combined with PMB; (ii) adsorbent treatment only; (iii) PMB treatment only. The influence on inflammation was tested by determination of the cytokine levels after incubation of differently pre-treated plasma samples with native blood cells.
Mentions: To verify whether the combination of adsorptive cytokine removal and PMB infusion is more effective than one of these treatments, an experiment as schematically displayed in Figure 1 was conducted. This experiment was carried out with blood from three different volunteers.Figure 1.

Bottom Line: The formed LPS-PMB complex has lower inflammatory activity in blood, which results in highly reduced cytokine secretion.Furthermore, the combination of cytokine removal by adsorbent treatment with LPS inactivation by PMB dosage leads to strong suppression of inflammatory effects in blood in an in vitro model.Inactivation of endotoxins by low-dose intravenous PMB infusion or infusion into the extracorporeal circuit during blood purification can be applied to overcome the urgent need for endotoxin elimination not only in treatment of sepsis, but also in liver failure.

View Article: PubMed Central - PubMed

Affiliation: Department for Health Sciences and Biomedicine, Danube University Krems, Krems, Austria Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstra├če 14, A-1090 Vienna, Austria stephan.harm@donau-uni.ac.at.

No MeSH data available.


Related in: MedlinePlus